Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06082349
Other study ID # NL84169.068.23
Secondary ID 2021038374METC23
Status Recruiting
Phase N/A
First received
Last updated
Start date December 18, 2023
Est. completion date March 1, 2029

Study information

Verified date January 2024
Source Maastricht University Medical Center
Contact Alieske Kleeven, MSc
Phone +31(0)433877481
Email alieske.kleeven@mumc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this randomized controlled trial is to compare the effectiveness and cost-effectiveness of lymphaticovenous anastomosis (LVA) with sham surgery for patients suffering from unilateral cancer-related lymphedema in either the upper or lower extremity. It aims to answer whether LVA is more effective than sham surgery in terms of improvement in Lymph-ICF score. A total of 110 participants will be allocated randomly into two groups at a 1:1 ratio. The first group will receive lymphaticovenous anastomosis (LVA), while the second group will undergo sham surgery.


Description:

One of the most debilitating side effects of cancer treatment is cancer-related lymphedema (CRL), with an overall incidence of 15.5%. To date, there is no definite cure for lymphedema. Conservative therapy, namely complex decongestive therapy is the golden standard for the treatment. Lymphaticovenous anastomosis (LVA) might be a promising treatment modality for patients with CRL, but available studies are small and the quality is lacking. No large-scale prospective or randomized studies have been published on the efficacy of LVA. The main objective of this randomized controlled trial is to assess whether LVA is more effective than sham surgery in terms of improvement in Lymph-ICF score, volume reduction, reduction of complex decongestive therapy, and cost-effectiveness. The study will take place in three centers in the Netherlands: Maastricht University Medical Center, Radboud University Medical Center, and Erasmus University Medical Center. The patients will be randomly distributed into two groups: the LVA group or the Sham group. Both procedures are performed under local anesthesia. Patients in both groups are subject to minor surgical complications (wound infection, bleeding, wound dehiscence). Special care will be taken to prevent damage to lymphatic vessels in the Sham group, to allow a future LVA operation once the study ends. The follow-up moments will be at 3, 6, 12, 18, and 24 months. Additionally, a subset of patients will partake in an annual extended follow-up, ongoing until the start of the analysis. Each follow-up moment will last 45 minutes in total. The patient also receives two digital questionnaires at each follow-up moment.


Recruitment information / eligibility

Status Recruiting
Enrollment 110
Est. completion date March 1, 2029
Est. primary completion date March 1, 2029
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Treated for cancer and underwent treatment of either axillary or inguinal lymph nodes or radiotherapy; - Early stage lymphedema (ISL I-II) in the upper or lower extremity, and diagnosed by lymphoscintigraphy for the lower extremity; - Unilateral lymphedema; - Viable lymphatic vessels as determined by indocyanine green (ICG)Lymphography (stage II-III); - Refractory lymphedema that underwent at least three months of conservative treatment; - Informed consent. Exclusion Criteria: - History of lymphatic reconstruction in the past 10 years; - Late-stage lymphedema of the extremity (ISL classification = II lymphedema) with evident fat deposition and/or fibrosis; - Patients with active distant metastases, treated with palliative intent; - Patients with the active treatment of primary cancer, i.e. surgery, radiotherapy, and/or chemotherapy. Note: patients receiving adjuvant targeted and/or endocrine treatment are eligible; - Edema due to venous insufficiency, evaluated by venous duplex ultrasound of the deep and superficial venous system; - Active infection in the lymphedematous extremity; - Bilateral lymphedema; - Lymphedema present in genital or breast area only; - Primary lymphedema; - Non-viable lymphatic system as determined by ICG Lymphography (stages IV and V).

Study Design


Intervention

Procedure:
Lymphaticovenous anastomosis
Lymphaticovenous anastomosis (LVA) involves connecting a lymphatic vessel to a adjacent vein of similar size, thereby facilitating the ouflow of lymphatic fluid in patients suffering from secondary lymphedema
Sham surgery
Sham surgery involves the process of surgery, including local anesthesia and incisions, but no LVA is made.

Locations

Country Name City State
Netherlands Maastricht University Medical Center Maastricht Limburg
Netherlands Radboud University Medical Center Nijmegen Gelderland
Netherlands Erasmus University Medical Center Rotterdam Zuid-Holland

Sponsors (3)

Lead Sponsor Collaborator
Maastricht University Medical Center Erasmus Medical Center, Radboud University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline in the Lymph-ICF Score at 12 and 24 months The Dutch version of the 'Lymphedema Functioning, Disability, and Health" (Lymph-ICF) questionnaire is used. There are two versions of the Lymph-ICF; one for the upper extremity and one for the lower extremity. The questionnaires assess the impairments in function, activity limitations, and participation restrictions of patients with lymphedema. It is a validated, disease-specific questionnaire, consisting of items across 5 domains. Each item is scored on a VAS, ranging from 0 to 100. Baseline, 3, 6, 12, 18 and 24 months post-operatively and afterwards annualy during the extended follow-up, lasting up to the start of the first analysis (maximally 3 years extra or 3 additional visits).
Secondary Change from baseline in excess limb volume The excess limb volume will be measured with BioImpedance Spectroscopy (BIS). With a bioimpedance device, the volume of the extremities can be measured together with the fluid in different compartments of the extremities. Baseline, 3, 6, 12, 18 and 24 months post-operatively and afterwards annualy during the extended follow-up, lasting up to the start of the first analysis (maximally 3 years extra or 3 additional visits).
Secondary Change from baseline in extremity circumference measured by the Upper and Lower Extremity Lymphedema (UEL and LEL) indices The extremity circumference will be measured using measuring tape according to the fixed measuring points of the UEL- and LEL-indices. The UEL- and LEL-indices are corrected for BMI. Baseline, 3, 6, 12, 18 and 24 months post-operatively and afterwards annualy during the extended follow-up, lasting up to the start of the first analysis (maximally 3 years extra or 3 additional visits).
Secondary Change from baseline in the use of conservative treatment Discontinuation of conservative treatment, being complex decongestive therapy, will be assessed with a patient diary to record the frequency of treatments received (i.e. skin therapy visits, number of compression garments, etc.). Baseline, 3, 6, 12, 18 and 24 months post-operatively and afterwards annualy during the extended follow-up, lasting up to the start of the first analysis (maximally 3 years extra or 3 additional visits).
Secondary Postoperative complications All postoperative complications for both treatment groups will be recorded to monitor safety. SAEs will be directly reported to the sponsor. Baseline, 3, 6, 12, 18 and 24 months post-operatively and afterwards annualy during the extended follow-up, lasting up to the start of the first analysis (maximally 3 years extra or 3 additional visits).
Secondary Patency of the LVA The patency of the LVAs will be measured with ICG lymphography 12 and 24 months post-operatively and afterwards annualy during the extended follow-up, lasting up to the start of the first analysis (maximally 3 years extra or 3 additional visits).
Secondary Patient costs, QALYs, and incremental cost-effectiveness Patients costs are registered by the patient in the patient diary. The QALY will be calculated using the EQ-5D-5L questionnaire. The EQ-5D is a questionnaire responsive to changes in health in cancer-patients after the conclusion of treatment. , lasting up to the start of the first analysis (maximally 3 years extra or 3 additional visits).
See also
  Status Clinical Trial Phase
Terminated NCT04858230 - LymphoPilot Test for Limb Lymphedema N/A
Completed NCT04575636 - MRL in the Upper Extremity N/A
Completed NCT03252145 - Treatment of Breast Cancer-related Lymphedema With a Negative Pressure Device N/A
Active, not recruiting NCT05441943 - Lymphaticovenous Anastomosis as Treatment for Lymphedema N/A
Completed NCT05754346 - Does Inclusion of Diaphragmatic Breathing Exercises in Complete Decongestive Therapy Provide Further Benefits in Patients With Breast Cancer Related Lymphedema N/A
Not yet recruiting NCT06264817 - Auto-Adjustable MOBIDERm Autofit Armsleeve in the Management of Upper Limb Lymphedema. N/A
Completed NCT06399458 - The Relationship Between Primary Lymphedema and Joint Hypermobility
Recruiting NCT06302361 - Lymphovenous Anastomosis for Breast Cancer Lymphedema N/A
Active, not recruiting NCT06278298 - Different Level of ECSWT in Post Mastectomy Lymphedema N/A
Completed NCT05037708 - Effects of Physiotherapy in the Treatment of Lymphedema After Breast Cancer N/A
Not yet recruiting NCT02453295 - Testing an Intervention to Foster Hope for Cancer Survivors With Lymphedema N/A
Completed NCT05660590 - Effect of Different Bandage Interface Pressures on Breast Cancer Related Lymphedema N/A
Withdrawn NCT02458391 - Complete Decongestive Therapy in Breast Cancer-Related Lymphedema N/A
Completed NCT04766489 - Evaluation of the Treatment Response in Breast Cancer Related Lymphedema N/A
Enrolling by invitation NCT04165512 - Effectiveness of Stellate Ganglion Block in Breast Cancer Related Lymphedema N/A
Recruiting NCT05762224 - Comparative Effects of KT and PG on UE Lymphedema and Functional Disability After Mastectomy N/A
Recruiting NCT05142800 - Screening For BCRL In Targeted Therapy For Breast Cancer
Recruiting NCT06012786 - Myofascial Pain Syndrome in Patients With Breast Cancer-related Lymphedema
Not yet recruiting NCT06113627 - Lymphatic Response to Resistance Exercise in Breast Cancer Survivors N/A
Completed NCT06036173 - Body Awareness and Functionality in Lymphedema